ELTX
HealthcareElicio Therapeutics, Inc.
$7.86
$-0.19 (-2.36%)
Jan 5, 2026
Price History (1Y)
Analysis
Elicio Therapeutics, Inc. is a biotechnology company operating in the healthcare sector. The company has a market capitalization of $135.65M and employs 32 individuals. The financial health of Elicio Therapeutics is characterized by significant net losses, with net income totaling -$45,857,000 over the trailing twelve months. Additionally, the company's EBITDA stands at -$42,108,000, indicating substantial operating expenses relative to revenue. The balance sheet shows $20.61M in cash and $15.06M in debt, resulting in a debt-to-equity ratio of 394.57. The valuation context for Elicio Therapeutics is marked by negative forward P/E (-5.22) and EV/EBITDA (-3.21) ratios. The company's price to book ratio stands at 35.57. These metrics provide context for the company's value in relation to its earnings and financial performance.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph nodetargeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph nodetargeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph nodetargeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $135.65M
- P/E Ratio
- N/A
- 52-Week High
- $12.62
- 52-Week Low
- $4.60
- Avg Volume
- 101.24K
- Beta
- 2.15
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 32